In breast cancer, the activation of the pathway in CSCs expressing GLI1 or GLI2 through Hh ligands or inhibition of GLI1 or GLI2 using cyclobutrazine or siRNA results in a change in BMI-1 expression. This evidence concerns the gene GLI1 and breast carcinoma.